41390
document
A prospective randomized trial of topical pimecrolimus for cetuximab-associated acnelike eruption . BACKGROUND Clinical trials addressing the acneiform rash associated with epidermal growth factor receptor inhibitors are lacking . OBJECTIVE We evaluated the ability of topical pimecrolimus to reduce the severity of cetuximab-related facial rash . METHODS In all , 24 patients with metastatic colorectal cancer with cetuximab facial rash received twice daily pimecrolimus application for 5 weeks to half of the face . At baseline , week 2 , and week 5 , a dermatologist performed facial lesion counts , patients reported perceived severity of rash-related symptoms , and standardized facial photographs were obtained for blinded evaluation of global rash severity . RESULTS Treatment sides had greater decrease in lesion counts than observation sides of face at weeks 2 ( P < .001 ) and 5 ( P = .02 ) . However , there were no significant differences in patients ' assessment of symptoms and in review of facial photographs for rash severity between treatment and observation sides . LIMITATIONS This study was not placebo controlled . CONCLUSIONS Pimecrolimus application did not translate into clinically meaningful benefit for patients with cetuximab-related facial rash .
41391
Intervention_Pharmacological
pimecrolimus
41392
Intervention_Pharmacological
pimecrolimus
41393
Intervention_Pharmacological
pimecrolimus
41394
Intervention_Pharmacological
Pimecrolimus
41395
Outcome_Physical
lesion counts
41396
Outcome_Physical
rash severity
41397
Participant_Condition
cetuximab-associated acnelike eruption
41398
Participant_Condition
cetuximab-related facial rash .
41399
Participant_Sample-size
24
41400
Participant_Condition
metastatic colorectal cancer with cetuximab facial rash
41401
Participant_Condition
cetuximab-related facial rash